J&J: to present new data at ELCC

(CercleFinance.com) - Johnson & Johnson will present new oncology data at the 2025 European Lung Cancer Congress (ELCC).


The group will announce overall survival (OS) results from the MARIPOSA phase 3 trial evaluating RYBREVANT (amivantamab-vmjw) plus LAZCLUZE TM (lazertinib) versus osimertinib in the first-line treatment of patients with EGFR-mutated non-small cell lung cancer.

These most recent and compelling overall survival data for first-line treatment with RYBREVANT and LAZCLUZE fundamentally change treatment discussions and transform expectations about how long patients will live. Johnson & Johnson said.


Copyright (c) 2025 CercleFinance.com. All rights reserved.